Hodgkin lymphoma: Diagnosis, Treatment, and Side Effect Management
Recorded on: March 29, 2024
Recorded on: March 29, 2024
Estimated Time to Complete: 1.5 hours
1.5 CE Credits/Contact hours for nurses and social workers available until: January 24, 2026
Format: Non-interactive recorded webinar
Target Audience
Oncology nurse practitioners, nurses, and social workers involved in the care of patients with Hodgkin lymphoma (HL).
Course content level for social workers: all levels
Description
This education program provides in-depth information about Hodgkin lymphoma (HL). Participants will gain thorough understanding of the subtypes of HL, the latest tests and techniques used to diagnose HL, up-to-date treatment options, what the goals of treatment are, and strategies to manage side effects, including surveillance of long-term and late effects. This program aims to empower participants with the knowledge and resources needed to make informed decisions about treating HL and providing patient and family education and support.
Learning Objectives
Upon completion of this activity, participants will:
- Describe the various subtypes of Hodgkin lymphoma (HL)
- Identify tests used to diagnose disease and monitor treatment of HL
- Explain the overarching goals of treatment for the subtypes of HL
- Explain approved and emerging treatment options for HL, including stem cell transplantation, and the role of clinical trials
- Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for HL
Faculty
David Awad, Pharm D, BCOP
Speaker
Clinical Pharmacist Specialist
Division of Blood Disorders
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ
Matthew Matasar, MD
Speaker
Chief of Blood Disorders
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ
Tara McCabe, APN, AOCNP, MSN
Speaker
Advanced Practice Nurse
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ
Continuing Education Information
Nursing Continuing Professional Development
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.
Nurse Practitioner Continuing Education
This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to 1.5 contact hours of accredited education.
There are no fees for participating in or receiving credit for this activity.
Providers
This activity is provided by The Leukemia & Lymphoma Society.
Supporters
There is no commercial support associated with this CE activity.
Participants gain access to the webinar via the participation button above.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.